N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Study hypothesis: N-acetylcysteine (NAC) can reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Clinica Universidad de Navarra, Universidad de Navarra
• Treatments: Acetylcysteine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Hepatectomy

Exclusion Criteria:

• ASA 4

• Cirrhosis

• Creatinine > 1.2 mg/dL

• Associate surgery (pancreatic or splenectomy)

• Intraoperative bleeding > 2 L.

• Active infection of inflammatory disease